P/E ratio for Botanix Pharmaceuticals (BOT.AX)
P/E ratio at the end of 2024: -33.7
According to Botanix Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -17.5094. At the end of 2024 the company had a P/E ratio of -33.7.
P/E ratio history for Botanix Pharmaceuticals from 2001 to 2024
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | -33.7 | 157.23% |
| 2023 | -13.1 | 231.63% |
| 2022 | -3.95 | -81.07% |
| 2021 | -20.9 | 933.05% |
| 2020 | -2.02 | -73.84% |
| 2019 | -7.72 | 78.86% |
| 2018 | -4.32 | 29.13% |
| 2017 | -3.34 | 70.67% |
| 2016 | -1.96 | -10.48% |
| 2015 | -2.19 | 50.51% |
| 2014 | -1.45 | 486.2% |
| 2013 | -0.2481 | -36.17% |
| 2012 | -0.3886 | -31.6% |
| 2011 | -0.5681 | -80.77% |
| 2010 | -2.95 | -35.42% |
| 2009 | -4.57 | -3.83% |
| 2008 | -4.76 | -0.47% |
| 2007 | -4.78 | 2.82% |
| 2006 | -4.65 | 1081.25% |
| 2005 | -0.3934 | -85.54% |
| 2004 | -2.72 | 131.4% |
| 2003 | -1.18 | -25.66% |
| 2002 | -1.58 | -89.37% |
| 2001 | -14.9 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.